TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)

Study acronym: CHANCE2602
StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Zhongda Hospital
44 trials monitored
See 2 trials at risk
Liver Cancer
1,602 trials monitored
See 70 trials at risk
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT07836309
Lead Sponsor Zhongda Hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC)
Related terms Carcinoma, Hepatocellular
Enrollment 596 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov